Alnylam Pharmaceuticals SG&A decreased by 0.9% to $322.55M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 34.4%, from $239.95M to $322.55M. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 18.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $145.32M | $142.08M | $186.38M | $154.47M | $169.98M | $235.86M | $210.34M | $183.66M | $214.69M | $199.18M | $198.12M | $210.80M | $248.40M | $220.99M | $295.34M | $239.95M | $323.31M | $322.08M | $325.37M | $322.55M |
| QoQ Change | — | -2.2% | +31.2% | -17.1% | +10.0% | +38.8% | -10.8% | -12.7% | +16.9% | -7.2% | -0.5% | +6.4% | +17.8% | -11.0% | +33.6% | -18.8% | +34.7% | -0.4% | +1.0% | -0.9% |
| YoY Change | — | — | — | — | +17.0% | +66.0% | +12.9% | +18.9% | +26.3% | -15.6% | -5.8% | +14.8% | +15.7% | +11.0% | +49.1% | +13.8% | +30.2% | +45.7% | +10.2% | +34.4% |
Range$142.08M – $325.37M
CAGR+18.3%
Avg YoY Growth+21.5%
Median YoY Growth+16.3%
SG&A at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's sg&a?
- Alnylam Pharmaceuticals (ALNY) reported sg&a of $322.55M in Q1 2026.
- How has Alnylam Pharmaceuticals's sg&a changed year-over-year?
- Alnylam Pharmaceuticals's sg&a increased by 34.4% year-over-year, from $239.95M to $322.55M.
- What is the long-term trend for Alnylam Pharmaceuticals's sg&a?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's sg&a has grown at a 18.2% compound annual growth rate (CAGR), from $620.64M to $1.21B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.